Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoCHGCF +3.27%85 EV-to-EBITDA is 15.69 as of Aug. 04, 2026, which is 29% below its 10-year median of 21.96. GuruFocus rates CHGCF with a GF Score™ of 85/100 and a GF Value™ of $47.53 (Fairly Valued). The stock has 1 warning sign investors should review. Among 746 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 57.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chugai Pharmaceutical Co's enterprise value is $65,989 Mil.
Chugai Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $4,206 Mil. Therefore, Chugai Pharmaceutical Co's EV-to-EBITDA for today is 15.69.
The historical rank and industry rank for Chugai Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
CHGCF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.03 Med: 21.96 Max: 39.8
Current: 15.69
During the past 13 years, the highest EV-to-EBITDA of Chugai Pharmaceutical Co was 39.80. The lowest was 9.03. And the median was 21.96.
CHGCF's EV-to-EBITDA is ranked worse than 57.91% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.08
vs CHGCF: 15.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Chugai Pharmaceutical Co (OTCPK:CHGCF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chugai Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Chugai Pharmaceutical Co's share price for today is $43.675.
Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.839.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's EV-to-EBITDA falls into.
Chugai Pharmaceutical Co's current Enterprise Value is $65,989 Mil.
Chugai Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,206 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (CHGCF) has a EV-to-EBITDA of 15.69 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chugai Pharmaceutical Co. This is 29% below median its historical median of 21.96. Over the past decade, Chugai Pharmaceutical Co's EV-to-EBITDA has ranged from 9.03 to 39.80. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #432 out of 746 companies in the Drug Manufacturers industry, placing it in the top 57.9%.
Is Chugai Pharmaceutical Co's EV-to-EBITDA too high?
Chugai Pharmaceutical Co's current EV-to-EBITDA of 15.69 is 29% below median its 10-year median of 21.96. Over the past 10 years, this metric has ranged from a low of 9.03 to a high of 39.80. The Drug Manufacturers industry median EV-to-EBITDA is 13.08. Chugai Pharmaceutical Co's value of 15.69 is 20% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #432 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #432 out of 746 companies for EV-to-EBITDA. This places Chugai Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.08. Chugai Pharmaceutical Co's value of 15.69 is 20% above this benchmark. Historically, Chugai Pharmaceutical Co's own EV-to-EBITDA has ranged from 9.03 to 39.80 over the past decade. While the company's 10-year median is 21.96 vs. the industry median of 13.08, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.08, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current EV-to-EBITDA of 15.69 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chugai Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current EV-to-EBITDA is 15.69, which is 29% below median its own 10-year median of 21.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Fairly Valued. The stock's GF Value™ is $47.53, compared to a current price of $43.68 — trading 8.1% below its estimated fair value. The current EV-to-EBITDA is 15.69, which is 29% below median its 10-year median of 21.96 and 20% above the Drug Manufacturers industry median of 13.08. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current EV-to-EBITDA is 15.69 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $43.68 is trading 8.1% below its estimated GF Value™ of $47.53.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCF:
EV-to-EBITDA: 15.69 (29% below median its 10-year median of 21.96)
GF Value™: $47.53 vs. price of $43.68 (8.1% below fair value)
Industry Position: 20% above the Drug Manufacturers median (#432 of 746)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score
Get the complete analysis for CHGCF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
